Deccan Hospital leads public awareness campaign on Alzheimer’s prevention

Alzheimer’s disease, the most common cause of dementia,is emerging asoneofthe greatest public healthchallenges ofthe 21stcentury.Aslifeexpectancyincreases,thenumberofindividualsliving with dementia continues to rise worldwide. Although there is still no cure, 2026 has brought renewed optimism with advances in early diagnosis, disease-modifying therapies, and, most importantly, growing evidence that asubstantialproportionofAlzheimer’sdiseasemaybepreventablethrough lifestyle Modification.

A New Era in Alzheimer's Treatment:

For decades, treatment focused mainly on improving symptoms using medications such as cholinesterase inhibitors and memantine. Today, the landscape is changing.

Disease-modifying therapies such as donanemab and lecanemab, which target amyloid-beta plaques in the brain,havedemonstratedtheabilitytoslowcognitive

declineincarefullyselectedpatientswithearlyAlzheimer’sdisease.These treatments are most effective when initiated during the mild cognitive impairment or early dementia stage rather than advanced disease.

However,theyarenotcuresandrequirecarefulpatientselectionbecauseof potential adverse effects, including amyloid-related imaging abnormalities (ARIA), necessitating MRI monitoring.

The Revolution inEarlyDiagnosis

Perhaps the most exciting advance in 2026 is the rapid development of blood-based and CSF based biomarkers.

NewplasmabiomarkerssuchaspTau217,pTau181andAβ42canidentify Alzheimer’s pathology with remarkable accuracy, reducing dependence on costly PET scans and invasive lumbar punctures. Research also suggests that newer blood tests may estimate how many years remain before symptomsappear,openingthedoortopreventiveinterventionsmuchearlier in the disease process.

Early diagnosis enables timely counselling, better planning, appropriate treatment, and participation in clinical trials.